News
Interim report January – September 2022
Oslo, Norway, November 1, 2022 – Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for the…
Genetic Analysis appoints Sedermera Corporate Finance AB to act as a liquidity provider for the Company´s share
Oslo, Norway, September 1, 2022 – Genetic Analysis AS (“GA” or “the Company”) has appointed Sedermera Corporate Finance as the…
Interim report January – June 2022
Oslo, Norway, August 18, 2022 – Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for the…
Genetic Analysis and Servatus enter Strategic Collaboration Agreement to develop new microbiome diagnostic and therapeutic solutions
The Strategic Collaboration Agreement will enable both parties to utilise extensive knowledge sharing for microbiome diagnostics and biotherapeutics development Genetic…
Genetic Analysis AS: Mandatory notification of trade – Primary Insider
OSLO, NORWAY – 20 May 2022: Genetic Analysis AS (“GA” or “the Company”) announce that a member of the management…
Genetic Analysis AS and Omnigene Medical Technologies Ltd. enter a distribution agreement to launch GA-map® in the United Arabic Emirates (UAE) market
OSLO, NORWAY – May 19, 2022: Molecular diagnostics specialist, Genetic Analysis AS (“GA”) hereby announces that GA has entered a…
Interim report January – March 2022
Oslo, Norway, May 13, 2022 – Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for the…
Minutes from the Annual General Meeting 2022 in Genetic Analysis AS
Oslo, Norway, April 29, 2022 – Genetic Analysis AS (the “Company”, Ticker: GEAN) held its Annual General Meeting on April…
Notice of Annual General Meeting 2022
Oslo, Norway, April 21, 2022 – Notice is hereby served that the Annual General Meeting of Genetic Analysis AS (the…
Publication of Genetic Analysis’ 2021 Annual Report
(Oslo, April 21, 2022) Genetic Analysis AS (“GA” or “the Company”) hereby publishes the Annual Report for the financial year…
Genetic Analysis strengthens its management team by hiring a Head of Operations
OSLO, NORWAY – 4 March 2022: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces today that the…
Year-End Report October – December 2021
(Oslo, 18 February 2022) Genetic Analysis AS (“GA” or “the Company”) hereby publishes the year-end report for the period 1…
IMD – Institut für Medizinische Diagnostik launches the GA-map® Microbiome Test in Germany
OSLO, NORWAY/BERLIN, GERMANY – 15 February 2022: Microbiome DX company Genetic Analysis AS (“GA”) and Institut für Medizinische Diagnostik (“IMD”),…
The Microbiome Test from Genetic Analysis AS launched on a new technology platform, GA-map® Dysbiosis Test kit now commercially available on the Luminex MAGPIX® system
OSLO, NORWAY – 1. February 2022: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces that the Company…
Genetic Analysis AS (GA) reports first commercial sales of the enhanced GA-map® Dysbiosis Test version 2
OSLO, NORWAY – 27th January 2022: Today, GA achieved another important milestone; first commercial sales of the new and enhanced…